Publication date: Jul 01, 2025
Post-acute sequelae of COVID-19 (PASC) are a complex clinical condition that requires a better understanding of its underlying biological mechanisms. In this study, we assessed hundreds of virological, serological, immunological, and tissue damage biomarkers in two cohorts of patients who had experienced either mild (n = 270) or severe (n = 188) COVID-19, 6 to 9 months post-initial infection, and in which 40% and 57. 4% of patients, respectively, developed PASC. Blood analysis showed that the main differences observed in humoral, viral, and biological biomarkers were associated with the initial COVID-19 severity, rather than being specifically linked to PASC. However, patients with PASC displayed altered CD4 and CD8 memory T cell subsets, with higher cytokine-secreting cells and increased terminally differentiated CD45RA effector memory T cells (TEMRA). Elevated SARS-CoV-2-specific T cells responsive to nucleocapsid/membrane proteins with a TEMRA phenotype were also observed. A random forest model identified these features and initial symptom duration as top variables discriminating PASC, achieving over 80% classification accuracy.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Post-acute Sequelae of COVID-19 |
| disease | MESH | infection |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | COVID-19 |
| disease | IDO | blood |
| disease | IDO | cell |
| disease | IDO | symptom |
| disease | MESH | Sequelae |
| drug | DRUGBANK | Tretamine |
| drug | DRUGBANK | Serine |
| drug | DRUGBANK | Dimercaprol |
| disease | MESH | dyspnea |
| disease | MESH | cognitive impairments |
| disease | MESH | anosmia |
| disease | MESH | ageusia |
| disease | MESH | inflammation |
| disease | MESH | heart failure |